EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa

Thomas P Lodise iD, Engels N Obi, Alexandre H Watanabe, Emre Yucel, Jae Min, Brian H Nathanson

Journal of Antimicrobial Chemotherapy · 04.11.2024 · 79 (11) · 2954-2964

DOI: 10.1093/jac/dkae313 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 11.09.2024. Verfasst von Thomas P Lodise und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY, USA. Hauptthemen laut MEDLINE: Drug Combinations, Cephalosporins, Ceftazidime, Azabicyclo Compounds. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ceftolozane/tazobactam and ceftazidime/avibactam are commonly used in patients with MDR-Pseudomonas aeruginosa (PSA) pneumonia (PNA). This study compared outcomes between non-COVID-19 hospitalized patients with MDR-PSA PNA who received ceftolozane/tazobactam or ceftazidime/avibactam.

Methods

The study included non-COVID-19 adult hospitalized patients with MDR-PSA PNA in the PINC AI Healthcare Database (2016–22) who received ceftolozane/tazobactam or ceftazidime/avibactam within 3 days of index culture for ≥2 days. Outcomes were mortality, recurrent MDR-PSA PNA, discharge destination, post-index culture day length of stay (LOS) and costs (in US dollars, USD), and hospital readmission.

Results

The final sample included 197 patients (117 ceftolozane/tazobactam, 80 ceftazidime/avibactam). No significant differences were observed in mortality and post-index culture LOS and costs between groups. In the multivariable analyses, patients who received ceftolozane/tazobactam versus ceftazidime/avibactam had lower recurrent MDR-PSA PNA (7.9% versus 18.0%, P = 0.03) and 60 day PNA-related readmissions (11.1% versus 28.5%, P = 0.03) and were more likely to be discharged home (25.8% versus 9.8%, P = 0.03). Compared with ceftazidime/avibactam patients, ceftolozane/tazobactam patients had lower adjusted median total antibiotic costs (5052 USD versus 8099 USD, P = 0.003) and lower adjusted median comparator (ceftolozane/tazobactam or ceftazidime/avibactam) antibiotic costs (3938 USD versus 6441 USD, P = 0.005). In the desirability of outcome ranking (DOOR) analysis, a ceftolozane/tazobactam-treated patient was more likely to have a more favourable outcome than a ceftazidime/avibactam-treated patient [DOOR probability: 59.6% (95% CI: 52.5%–66.8%)].

Conclusions

Early treatment with ceftolozane/tazobactam may offer some clinical and cost benefits over ceftazidime/avibactam in patients with MDR-PSA PNA. Further large-scale studies are necessary to comprehensively understand the outcomes associated with these treatments for MDR-PSA PNA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug CombinationsCephalosporinsCeftazidimeAzabicyclo CompoundsTazobactamPseudomonas aeruginosaAnti-Bacterial AgentsPseudomonas InfectionsDrug Resistance, Multiple, BacterialHumansMaleFemaleMiddle AgedAgedTreatment OutcomeAdultPneumonia, BacterialRetrospective StudiesAged, 80 and over

Substanzen

Drug CombinationsCephalosporinsavibactam, ceftazidime drug combinationCeftazidimeceftolozane, tazobactam drug combinationAzabicyclo CompoundsTazobactamAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, 106 New Scotland Avenue, Albany, NY, USA.
  • Merck & Co., Inc., 2025 E Scott Ave, Rahway, NJ, USA.
  • OptiStatim LLC, 25 Willow Circle, Longmeadow, MA, USA.

ORCID-Profile: Thomas P Lodise

Förderung

  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc.

Zitieren

APA

Lodise, T. P., Obi, E. N., Watanabe, A. H., Yucel, E., Min, J., & Nathanson, B. H. (2024). Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 79(11), 2954-2964. https://doi.org/10.1093/jac/dkae313

Vancouver

Lodise TP, Obi EN, Watanabe AH, Yucel E, Min J, Nathanson BH. Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy. 2024;79(11):2954-2964. doi:10.1093/jac/dkae313

BibTeX
@article{Lodise2024,
  author = {Lodise, Thomas P and Obi, Engels N and Watanabe, Alexandre H and Yucel, Emre and Min, Jae and Nathanson, Brian H},
  title = {Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {11},
  pages = {2954--2964},
  doi = {10.1093/jac/dkae313}
}
Kostenlos starten →